BMO Capital analyst Alex Arfaei reiterated an Outperform rating and $75 on Bristol-Myers Squibb Co. (NYSE: BMY) following Q1 results ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View FDA

U.S. FDA Approves First Genetic Copies of Otsuka's Abilify (BMY) April 28, 2015 2:30 PM Bristol-Myers Squibb Announces Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt SecuritiesApril 28, 2015 7:49 AM Form 10-Q BRISTOL MYERS SQUIBB CO For: Mar 31April 28, 2015 7:39 AM Form 8-K BRISTOL MYERS SQUIBB CO For: Apr 28April 28, 2015 7:31 AM Bristol-Myers Squibb (BMY) Tops Q1 EPS by 20c; Adjusts FY15 EPS OutlookApril 28, 2015 7:31 AM Bristol-Myers Squibb Reports First Quarter Financial ResultsApril 28, 2015 7:30 AM